1H-Imidazole-4-butanimidamide | 135262-80-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1H-Imidazole-4-butanimidamide
• 英文别名: 4-(1H-imidazol-5-yl)butanimidamide
• CAS: 135262-80-5
• 化学式: C₇H₁₂N₄
• 分子量: 152.2
• InChiKey: DXLYSPKZUXSVKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  78.6
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• Imidazole derivatives as histamine H3-agonists
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0420396A2

  公开（公告）日：1991-04-03

  A pharmaceutical composition is described which comprises a pharmaceutically acceptable carrier and a compound of the formula (1) : or a pharmaceutically acceptable salt thereof wherein X is CH₂ or S, in an amount sufficient to stimulate selectively histamine H₃-receptors.

  一种药物组合物包括药学上可接受的载体和式 (1) ： 或其药学上可接受的盐，其中 X 是 CH₂ 或 S，其用量足以选择性地刺激组胺 H₃ 受体。
• HISTAMINE H3 AGONIST FOR USE AS THERAPEUTIC AGENT FOR LIPID/GLUCOSE METABOLIC DISORDER
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1938838A1

  公开（公告）日：2008-07-02

  The present invention provides a histamine receptor H3 protein agonist (e.g. Imetit) used for anti-obesity or suppression of food intake. In addition, the present invention also provides a method for assaying a compound having a histamine receptor H3 protein as a target of drug discovery, and a compound obtained by the aforementioned assay method. According to the present invention, it becomes possible to provide a novel intended use of a histamine receptor H3 protein agonist for anti-obesity or suppression of food intake. Moreover, it also becomes possible to provide a method for assaying a compound having the aforementioned protein as a target of drug discovery, and a compound obtained by the aforementioned assay method.

  本发明提供了一种组胺受体H3蛋白激动剂（如伊美替特），用于抗肥胖或抑制食物摄入。此外，本发明还提供了一种以组胺受体 H3 蛋白为药物发现靶点的化合物的检测方法，以及通过上述检测方法获得的化合物。根据本发明，有可能提供组胺受体 H3 蛋白激动剂在抗肥胖或抑制食物摄入方面的新型预期用途。此外，本发明还提供了一种以上述蛋白为药物发现靶点的化合物的检测方法，以及通过上述检测方法获得的化合物。
• Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder
  申请人：Yoshimoto Ryo

  公开号：US20100137391A1

  公开（公告）日：2010-06-03

  Disclosed are: novel use of an agonist histamine receptor H3 (e.g., Imetit) for prevention of obesity or the reduction of food intake; a method for evaluation of a compound for use as a therapeutic agent targeted to histamine receptor HR protein; and a compound provided by the method.